ERBB2 and breast cancer: However, even though PD-1/PD-L1 pathways are well discussed in literature, the exact mechanisms that lead to the overexpression of PD-L1 and their consequences in HER2+ BC patients are yet to be clearly understood [102,115,121,134,150,151].